{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:12Z","timestamp":1781639652332,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060517"],"award-info":[{"award-number":["82060517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260525"],"award-info":[{"award-number":["82260525"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212ACB206015"],"award-info":[{"award-number":["20212ACB206015"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung adenocarcinoma (LUAD) is the leading cause of cancer-related mortality worldwide, highlighting the urgent need for additional molecular biomarkers and therapeutic targets. Transcription factor AP-2\u03b1 (TFAP2A) is highly expressed in LUAD and is associated with poor prognosis. Sphingosine-1-phosphate phosphatae 2 (SGPP2\/SPP2) has been implicated in tumor progression in multiple cancer types; however, its functional role in LUAD cells and the underlying mechanisms remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bioinformatics analysis was conducted to elucidate the expression patterns of SGPP2 and TFAP2A. Quantitative real-time polymerase chain reaction (qRT-PCR), western blotting (WB), and immunohistochemistry (IHC) were performed to measure mRNA and protein expression levels. Cellular proliferation and cell cycle progression were evaluated using the Cell Counting Kit-8 (CCK-8) assay, 5-ethynyl-2\u2019-deoxyuridine (EdU) assay, colony formation assay, and flow cytometry. Migratory and invasive capabilities were evaluated using transwell and wound-healing assays. Lipid metabolism was assessed by measuring triglyceride (TG) and total cholesterol (TC) levels, using Oil Red O and Nile Red fluorescence staining. The regulatory relationship between TFAP2A and the SGPP2 promoter was confirmed using chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. Protein-protein interactions were investigated using co-immunoprecipitation (CoIP) assay. The in vivo tumorigenic potential was examined using a xenograft model in nude mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SGPP2 and TFAP2A were upregulated in LUAD. High SGPP2 expression is closely associated with lymph node metastasis. Functional experiments demonstrated that SGPP2 promotes LUAD cell proliferation, migration, and epithelial-mesenchymal transition (EMT). Under physiological conditions, TFAP2A transcriptionally activates SGPP2 in LUAD cells, whereas SGPP2 reciprocally inhibits TFAP2A expression. Downstream pathway analysis revealed that SGPP2 overexpression downregulated SGPP1 expression, leading to increased sphingosine-1-phosphate (S1P) levels in the cells. This, in turn, promotes intracellular lipid accumulation and phosphorylation of glycogen synthase kinase 3\u03b2 (GSK3\u03b2) at Ser9, thereby facilitating the nuclear translocation of \u03b2-catenin. Consequently, CyclinD1 expression is upregulated, ultimately driving LUAD progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGPP2 and TFAP2A are highly expressed in LUAD. SGPP2, which regulates S1P levels and is transactivated by TFAP2A, promotes lipid accumulation and activates the Wnt\/\u03b2-catenin signaling pathway to facilitate the progression of lung adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-07949-x","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:05:00Z","timestamp":1772607900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TFAP2A regulates SGPP2 transcription to promote lipid accumulation and activate the Wnt\/\u03b2-catenin signaling pathway to promote malignant progression in lung adenocarcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Qingqing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6551-4844","authenticated-orcid":false,"given":"Jinhong","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"1","key":"7949_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"7949_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10299","key":"7949_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"10125","key":"7949_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375.","journal-title":"Lancet"},{"issue":"Pt 2","key":"7949_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1042\/BJ20041771","volume":"387","author":"YJ Sigal","year":"2005","unstructured":"Sigal YJ, McDermott MI, Morris AJ. Integral membrane lipid phosphatases\/phosphotransferases: common structure and diverse functions. Biochem J. 2005;387(Pt 2):281\u201393.","journal-title":"Biochem J"},{"issue":"12","key":"7949_CR6","doi-asserted-by":"publisher","first-page":"113586","DOI":"10.1016\/j.celrep.2023.113586","volume":"42","author":"J Noujar\u00e8de","year":"2023","unstructured":"Noujar\u00e8de J, Carri\u00e9 L, Garcia V, et al. Sphingolipid paracrine signaling impairs keratinocyte adhesion to promote melanoma invasion. Cell Rep. 2023;42(12):113586.","journal-title":"Cell Rep"},{"issue":"10","key":"7949_CR7","doi-asserted-by":"publisher","first-page":"e0122771","DOI":"10.1371\/journal.pone.0122771","volume":"10","author":"J Barnawi","year":"2015","unstructured":"Barnawi J, Tran H, Jersmann H, et al. Potential Link between the Sphingosine-1-Phosphate (S1P) System and Defective Alveolar Macrophage Phagocytic Function in Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE. 2015;10(10):e0122771.","journal-title":"PLoS ONE"},{"issue":"8","key":"7949_CR8","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1096\/fj.201600394R","volume":"30","author":"WC Huang","year":"2016","unstructured":"Huang WC, Liang J, Nagahashi M, et al. Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans. FASEB J. 2016;30(8):2945\u201358.","journal-title":"FASEB J"},{"issue":"4","key":"7949_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cellsig.2006.09.004","volume":"19","author":"D Mechtcheriakova","year":"2007","unstructured":"Mechtcheriakova D, Wlachos A, Sobanov J, et al. Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal. 2007;19(4):748\u201360.","journal-title":"Cell Signal"},{"key":"7949_CR10","doi-asserted-by":"publisher","first-page":"670353","DOI":"10.3389\/fonc.2021.670353","volume":"11","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Zhang R, Zhang Y, et al. NUDT21 Promotes Tumor Growth and Metastasis Through Modulating SGPP2 in Human Gastric Cancer. Front Oncol. 2021;11:670353.","journal-title":"Front Oncol"},{"key":"7949_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.etap.2017.03.001","volume":"51","author":"L Lao","year":"2017","unstructured":"Lao L, Shen J, Tian H, Zhong G, Murray SS, Wang JC. Secreted phosphoprotein 24kD (Spp24) inhibits growth of hepatocellular carcinoma in vivo. Environ Toxicol Pharmacol. 2017;51:51\u20135.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"2","key":"7949_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbrc.2015.08.124","volume":"466","author":"CS Li","year":"2015","unstructured":"Li CS, Tian H, Zou M, et al. Secreted phosphoprotein 24 kD (Spp24) inhibits growth of human pancreatic cancer cells caused by BMP-2. Biochem Biophys Res Commun. 2015;466(2):167\u201372.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"7949_CR13","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.21873\/anticanres.11161","volume":"36","author":"L Lao","year":"2016","unstructured":"Lao L, Shen J, Tian H, et al. Secreted Phosphoprotein 24 kD Inhibits Growth of Human Prostate Cancer Cells Stimulated by BMP-2. Anticancer Res. 2016;36(11):5773\u201380.","journal-title":"Anticancer Res"},{"key":"7949_CR14","doi-asserted-by":"crossref","unstructured":"Zhang Y, Kong X, Xin S, Bi L, Sun X. Discovery of lipid metabolism-related genes for predicting tumor immune microenvironment status and prognosis in prostate cancer. J Oncol. 2022;2022:8227806.","DOI":"10.1155\/2022\/8227806"},{"issue":"8","key":"7949_CR15","doi-asserted-by":"publisher","first-page":"113060","DOI":"10.1016\/j.isci.2025.113060","volume":"28","author":"J Luo","year":"2025","unstructured":"Luo J, Ding Z, Chen D, et al. TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma. iScience. 2025;28(8):113060.","journal-title":"iScience"},{"issue":"1","key":"7949_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41419-025-07500-8","volume":"16","author":"Z Li","year":"2025","unstructured":"Li Z, Zhang C, Huang G, et al. Deletion of Tfap2a in hepatocytes and macrophages promotes the progression of hepatocellular carcinoma by regulating SREBP1\/FASN\/ACC pathway and anti-inflammatory effect of IL10. Cell Death Dis. 2025;16(1):245.","journal-title":"Cell Death Dis"},{"key":"7949_CR17","doi-asserted-by":"publisher","first-page":"106941","DOI":"10.1016\/j.prostaglandins.2024.106941","volume":"176","author":"X Zheng","year":"2025","unstructured":"Zheng X, Zhou J, Nie S, et al. TFAP2A activates CTHRC1 to influence the migration of lung adenocarcinoma cells by modulating fatty acid metabolism. Prostaglandins Other Lipid Mediat. 2025;176:106941.","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"4","key":"7949_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41419-021-03606-x","volume":"12","author":"Y Xiong","year":"2021","unstructured":"Xiong Y, Feng Y, Zhao J, et al. TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family\/TFAP2A\/PSG9\/TGF-\u03b2 signaling pathway. Cell Death Dis. 2021;12(4):352.","journal-title":"Cell Death Dis"},{"issue":"4","key":"7949_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41419-020-2434-z","volume":"11","author":"J Gong","year":"2020","unstructured":"Gong J, Lin Y, Zhang H, et al. Reprogramming of lipid metabolism in cancer-associated fibroblasts potentiates migration of colorectal cancer cells. Cell Death Dis. 2020;11(4):267.","journal-title":"Cell Death Dis"},{"key":"7949_CR20","doi-asserted-by":"publisher","first-page":"1516650","DOI":"10.3389\/fphar.2024.1516650","volume":"15","author":"Q Huang","year":"2024","unstructured":"Huang Q, Fan L, Gong M, Ren J, Chen C, Xie S. Metabolic reprogramming in lung cancer and its clinical implication. Front Pharmacol. 2024;15:1516650.","journal-title":"Front Pharmacol"},{"issue":"1","key":"7949_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/biof.1455","volume":"45","author":"LB Murad","year":"2019","unstructured":"Murad LB, da Silva Nogueira P, de Ara\u00fajo WM, et al. Docosahexaenoic acid promotes cell cycle arrest and decreases proliferation through WNT\/\u03b2-catenin modulation in colorectal cancer cells exposed to \u03b3-radiation. BioFactors. 2019;45(1):24\u201334.","journal-title":"BioFactors"},{"issue":"11","key":"7949_CR22","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1007\/s11064-021-03398-8","volume":"46","author":"JX Xu","year":"2021","unstructured":"Xu JX, Fang K, Gao XR, Liu S, Ge JF, Resveratrol Protects. SH-SY5Y Cells Against Oleic Acid-Induced Glucolipid Metabolic Dysfunction and Cell Injuries Via the Wnt\/\u03b2-Catenin Signalling Pathway. Neurochem Res. 2021;46(11):2936\u201347.","journal-title":"Neurochem Res"},{"key":"7949_CR23","doi-asserted-by":"crossref","unstructured":"Fhu CW, Ali A. Fatty acid synthase: an emerging target in cancer. Molecules. 2020;25(17).","DOI":"10.3390\/molecules25173935"},{"issue":"1","key":"7949_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","volume":"38","author":"C Cheng","year":"2018","unstructured":"Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38(1):27.","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"7949_CR25","doi-asserted-by":"publisher","first-page":"e0120647","DOI":"10.1371\/journal.pone.0120647","volume":"10","author":"Y Cai","year":"2015","unstructured":"Cai Y, Hirata A, Nakayama S, et al. CCAAT\/enhancer binding protein \u03b2 is dispensable for development of lung adenocarcinoma. PLoS ONE. 2015;10(3):e0120647.","journal-title":"PLoS ONE"},{"issue":"3","key":"7949_CR26","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"7949_CR27","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"7949_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499\u2013514.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8088","key":"7949_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41586-025-09663-y","volume":"647","author":"D Zhang","year":"2025","unstructured":"Zhang D, Rubio Rodr\u00edguez-Kirby LA, Lin Y, et al. Spatial dynamics of brain development and neuroinflammation. Nature. 2025;647(8088):213\u201327.","journal-title":"Nature"},{"key":"7949_CR30","doi-asserted-by":"crossref","unstructured":"Fan R, Baysoy A, Tian X, et al. Spatially resolved panoramic in vivo CRISPR screen via Perturb-DBiT. Res Sq. 2025.","DOI":"10.21203\/rs.3.rs-6481967\/v1"},{"key":"7949_CR31","doi-asserted-by":"crossref","unstructured":"Fan R, Zhang D, Rodr\u00edguez-Kirby L, et al. Spatial dynamics of mammalian brain development and neuroinflammation by multimodal tri-omics mapping. Res Sq. 2024.","DOI":"10.1101\/2024.07.28.605493"},{"issue":"10","key":"7949_CR32","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41587-023-01676-0","volume":"41","author":"Y Liu","year":"2023","unstructured":"Liu Y, DiStasio M, Su G, et al. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nat Biotechnol. 2023;41(10):1405\u20139.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"7949_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","volume":"23","author":"YJ Li","year":"2023","unstructured":"Li YJ, Zhang C, Martincuks A, Herrmann A, Yu H. STAT proteins in cancer: orchestration of metabolism. Nat Rev Cancer. 2023;23(3):115\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"7949_CR34","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41388-021-02148-y","volume":"41","author":"J Lin","year":"2022","unstructured":"Lin J, Xia L, Oyang L, et al. The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis and the pentose phosphate pathway activity. Oncogene. 2022;41(7):1024\u201339.","journal-title":"Oncogene"},{"issue":"Pt 11","key":"7949_CR35","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1099\/vir.0.055616-0","volume":"94","author":"JM Carr","year":"2013","unstructured":"Carr JM, Kua T, Clarke JN, et al. Reduced sphingosine kinase 1 activity in dengue virus type-2 infected cells can be mediated by the 3\u2019 untranslated region of dengue virus type-2 RNA. J Gen Virol. 2013;94(Pt 11):2437\u201348.","journal-title":"J Gen Virol"},{"issue":"7","key":"7949_CR36","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1074\/jbc.M510308200","volume":"281","author":"A Kihara","year":"2006","unstructured":"Kihara A, Anada Y, Igarashi Y. Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, and oligomerization. J Biol Chem. 2006;281(7):4532\u20139.","journal-title":"J Biol Chem"},{"key":"7949_CR37","doi-asserted-by":"publisher","first-page":"1564213","DOI":"10.3389\/fimmu.2025.1564213","volume":"16","author":"F Wu","year":"2025","unstructured":"Wu F, Feng Z, Wang X, et al. Sphingosine-1-phosphate stimulates colorectal cancer tumor microenvironment angiogenesis and induces macrophage polarization via macrophage migration inhibitory factor. Front Immunol. 2025;16:1564213.","journal-title":"Front Immunol"},{"issue":"22","key":"7949_CR38","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1002\/1873-3468.13933","volume":"594","author":"NJ Pyne","year":"2020","unstructured":"Pyne NJ, Pyne S. Recent advances in the role of sphingosine 1-phosphate in cancer. FEBS Lett. 2020;594(22):3583\u2013601.","journal-title":"FEBS Lett"},{"key":"7949_CR39","doi-asserted-by":"crossref","unstructured":"Niu Y, Zhu X, Ma D, Pan Q, Li X. Integrative phosphoproteomic and metabolomic analysis of disruption of metabolic homeostasis in breast cancer: a pilot study. Biochem Genet. 2025.","DOI":"10.1007\/s10528-025-11070-x"},{"issue":"30","key":"7949_CR40","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1038\/onc.2015.466","volume":"35","author":"R Bharti","year":"2016","unstructured":"Bharti R, Dey G, Ojha PK, et al. Diacerein-mediated inhibition of IL-6\/IL-6R signaling induces apoptotic effects on breast cancer. Oncogene. 2016;35(30):3965\u201375.","journal-title":"Oncogene"},{"issue":"10","key":"7949_CR41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/CAD.0000000000001648","volume":"35","author":"X Yang","year":"2024","unstructured":"Yang X, Wang C. SGPP2 is activated by SP1 and promotes lung adenocarcinoma progression. Anticancer Drugs. 2024;35(10):943\u201351.","journal-title":"Anticancer Drugs"},{"key":"7949_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semcdb.2020.03.009","volume":"107","author":"D Mart\u00ednez-Alonso","year":"2020","unstructured":"Mart\u00ednez-Alonso D, Malumbres M. Mammalian cell cycle cyclins. Semin Cell Dev Biol. 2020;107:28\u201335.","journal-title":"Semin Cell Dev Biol"},{"key":"7949_CR43","doi-asserted-by":"crossref","unstructured":"Pei B, Sun H, Xu L. Transcription factor TFAP2A drives the growth and metastasis and blocks ferroptosis of triple-negative breast cancer by activating PRAME transcription. Naunyn Schmiedebergs Arch Pharmacol. 2025.","DOI":"10.1007\/s00210-025-04359-6"},{"issue":"8","key":"7949_CR44","doi-asserted-by":"publisher","first-page":"10239","DOI":"10.1007\/s00210-025-03848-y","volume":"398","author":"J Yuan","year":"2025","unstructured":"Yuan J, Liu J, Fai R, Liu Z. TFAP2A facilitates the metastasis and radioresistance of esophageal cancer by promoting EGFR transcription. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(8):10239\u201348.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6630","key":"7949_CR45","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/387296a0","volume":"387","author":"Y Haupt","year":"1997","unstructured":"Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296\u20139.","journal-title":"Nature"},{"issue":"6","key":"7949_CR46","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.chembiol.2018.03.010","volume":"25","author":"L Liang","year":"2018","unstructured":"Liang L, Wang H, Shi H, et al. A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity. Cell Chem Biol. 2018;25(6):761\u2013e7745.","journal-title":"Cell Chem Biol"},{"key":"7949_CR47","doi-asserted-by":"crossref","unstructured":"Yang M, Lu Y, Zheng J, et al. PRICKLE3-USP9X interaction-mediated DVL2 deubiquitination promotes the progression of non-small cell lung cancer via canonical WNT pathway. Oncogene. 2025.","DOI":"10.1038\/s41388-025-03580-0"},{"issue":"12","key":"7949_CR48","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.7150\/ijbs.107130","volume":"21","author":"T Yu","year":"2025","unstructured":"Yu T, Li W, Meng X, et al. E3 ligase MKRN2 destabilizes PPP2CA proteins to inactivate canonical Wnt pathway and mitigates tumorigenesis of clear cell renal cell carcinoma. Int J Biol Sci. 2025;21(12):5361\u201377.","journal-title":"Int J Biol Sci"},{"key":"7949_CR49","doi-asserted-by":"crossref","unstructured":"Wang Y, Yang C, Guo L, et al. Targeting BACH1 by HPPE inhibits the Wnt\/\u03b2-catenin pathway and malignant phenotype in glioblastoma cells. Apoptosis. 2025.","DOI":"10.1007\/s10495-025-02183-0"},{"key":"7949_CR50","doi-asserted-by":"crossref","unstructured":"Wiese KE, Nusse R, van Amerongen R. Wnt signalling: conquering complexity. Development. 2018;145(12).","DOI":"10.1242\/dev.165902"},{"issue":"5831","key":"7949_CR51","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1126\/science.1137065","volume":"316","author":"J Bilic","year":"2007","unstructured":"Bilic J, Huang YL, Davidson G, et al. Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. Science. 2007;316(5831):1619\u201322.","journal-title":"Science"},{"issue":"6","key":"7949_CR52","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169(6):985\u201399.","journal-title":"Cell"},{"issue":"1","key":"7949_CR53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12964-024-01774-9","volume":"22","author":"L Jiang","year":"2024","unstructured":"Jiang L, Zhao Y, Liu F, et al. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting \u03b2-catenin activity via the PP2A-GSK3\u03b2 axis. Cell Commun Signal. 2024;22(1):391.","journal-title":"Cell Commun Signal"},{"issue":"6","key":"7949_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2005.04.010","volume":"1","author":"A Sundqvist","year":"2005","unstructured":"Sundqvist A, Bengoechea-Alonso MT, Ye X, et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 2005;1(6):379\u201391.","journal-title":"Cell Metab"},{"issue":"5","key":"7949_CR55","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2015.09.021","volume":"28","author":"C Cheng","year":"2015","unstructured":"Cheng C, Ru P, Geng F, et al. Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth. Cancer Cell. 2015;28(5):569\u201381.","journal-title":"Cancer Cell"},{"key":"7949_CR56","doi-asserted-by":"publisher","first-page":"603837","DOI":"10.3389\/fcell.2020.603837","volume":"8","author":"Z Wei","year":"2020","unstructured":"Wei Z, Liu X, Cheng C, Yu W, Yi P. Metabolism of Amino Acids in Cancer. Front Cell Dev Biol. 2020;8:603837.","journal-title":"Front Cell Dev Biol"},{"key":"7949_CR57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semcancer.2024.12.002","volume":"108","author":"Q Gu","year":"2024","unstructured":"Gu Q, Wang Y, Yi P, Cheng C. Theoretical framework and emerging challenges of lipid metabolism in cancer. Semin Cancer Biol. 2024;108:48\u201370.","journal-title":"Semin Cancer Biol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07949-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07949-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07949-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:13:47Z","timestamp":1781637227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07949-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7949"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07949-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Jiangxi Medical College, Nanchang University (Approval No.: (2025)CDYFYYLK(09\u2013029)) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients before sampling. The animal experiments were approved by the Laboratory Animal Welfare and Ethics Committee of the First Affiliated Hospital of Nanchang University (approval no. CDYFY-IACUC-202505GR094) and were performed in accordance with the governmental guidelines on the care and use of laboratory animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the final version of the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflict of interest was declared by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"490"}}